Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Glioblastoma Multiforme (GBM) Treatment Market Growth From $3.02 Billion In 2026 To $4.46 Billion By 2030 At A CAGR Of 10.2%
The glioblastoma multiforme (gbm) treatment market size has seen rapid expansion in recent years. It is projected to increase from $2.73 billion in 2025 to $3.02 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.7%. Historically, this growth can be attributed to several factors, including restricted survival outcomes, continued reliance on surgery and radiation, the standardization of chemotherapy, the expansion of neuro-oncology centers, and a rise in brain tumor diagnoses.
The glioblastoma multiforme (gbm) treatment market is projected to experience substantial expansion over the upcoming years. This market is predicted to reach $4.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. The anticipated market growth can be linked to factors such as advancements in targeted therapies, the broadening of immunotherapy pipelines, the embrace of precision medicine, heightened clinical trial activity, and an increase in research funding. Key developments expected during this period involve the increasing uptake of multimodal treatment regimens, enhanced application of tumor treating field therapy, a stronger emphasis on individualized gbm therapies, the widening of immunotherapy strategies, and refined post-surgical treatment protocols.
Get A Free Sample Report With In-Depth Market Insights:
Glioblastoma Multiforme (GBM) Treatment Market Growth Factors: What’s Supporting Expansion?
The increasing occurrence of brain disorders is projected to boost the growth of the glioblastoma multiforme (GBM) treatment market moving forward. Brain disorders involve the abnormal functioning of the brain as well as the nerves located throughout the human body and the spinal cord. The rising prevalence of brain disorders such as glioblastoma multiforme (GBM) can be attributed to various contributing factors like the aging population, compromised immune systems, overdiagnosis, ionizing radiation, air pollution, and other elements, which consequently generates a demand for brain disorder treatment to enhance well-being. For instance, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, approximately 433,300 Australians are living with dementia, a number expected to climb to 812,500 by 2054. Additionally, younger-onset dementia impacts around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the growing prevalence of brain disorders is a primary driver for the expansion of the glioblastoma multiforme (GBM) treatment market.
Glioblastoma Multiforme (GBM) Treatment Market Segment Trends And Revenue Contributors
The glioblastoma multiforme (gbm) treatment market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, R Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies
Glioblastoma Multiforme (GBM) Treatment Market Trends Shaping Long-Term Demand
Major companies operating in the market are prioritizing the development of innovative wearable and portable devices to sustain their position. These advancements aim to offer users enhanced functionality, convenience, and comfort, addressing the growing demand for accessible and efficient healthcare solutions. For instance, in 2023, Novocure, a Jersey-based oncology company, launched Optune Gio, an FDA-approved wearable and portable treatment system for patients newly diagnosed with glioblastoma (GBM). This device utilizes Tumor Treating Fields (TTFields), which are alternating electric fields that disrupt cancer cell division, potentially extending patient survival. Weighing only 2.7 pounds, Optune Gio is designed for comfort, allowing patients to wear it during daily activities.
Glioblastoma Multiforme (GBM) Treatment Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the glioblastoma multiforme (gbm) treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, Loxo Oncology Inc., Karyopharm Therapeutics Inc., EnGeneIC Ltd., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc
View The Full Glioblastoma Multiforme (GBM) Treatment Market Report:
Glioblastoma Multiforme (GBM) Treatment Market Regional Analysis And Top Geography
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
